PFE  Pfizer Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.25 (+0.84%)

Growth Price

Fairly valued

Stability Price

Overvalued by 61.46%

Company Metrics

  • 18.48 P/E
  • 3.78 P/S
  • 2.47 P/B
  • 1.615 EPS
  • 11.61% Cash ROIC
  • 1.39 Cash Ratio
  • 1.02 / 3.42 % Dividend
  • 25.14M Avg. Vol.
  • 190.8B Market Cap.

Company Description

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company's Biopharmaceutical segment's provides Lipitor for elevated LDL-cholesterol levels in the blood; Enbrel for rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis; Lyrica for post-herpetic neuralgia, diab...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Pfizer Inc.'s Earnings: Emerging Market Growth and Patent Expirations Square Off
Motley Fool - Oct 29, 2014
Having lost Lipitor, Viagra, and a number of other key therapies to generic competition in recent years, CEO Ian Read and Pfizer have made it clear that the company plans to grow its business organically and through acquisitions in order to get past ...
Pfizer Inc. (NYSE:PFE) Beats Expectations for Quarterly Results - Inside Trade
Pfizer CEO: Still exploring tax-inversion deal -
Drug firm Pfizer gets Bombay High Court nod for merger of Wyeth Ltd
Economic Times - 2 hours ago
NEW DELHI: Drug firm Pfizer today said the Bombay High Court has approved the amalgamation of Wyeth Ltd with the company. "The Hon'ble High Court of Judicature at Bombay on October 31, 2014 considered and approved the amalgamation of Wyeth Ltd ...
Pfizer beats sales and profit forecasts, mum on future deals
Reuters - Oct 28, 2014
(Reuters) - Pfizer Inc (PFE.N) reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans following its recent failed efforts ...
Pfizer (PFE) Stock Falls After Dropping Pain Drug - Oct 27, 2014
NEW YORK (TheStreet) -- Shares of Pfizer Inc. (PFE) are down by 0.21% to $29.05 after the pharmaceutical company notified Pain Therapeutics, Inc. (PTIE) that it has decided to discontinue its agreement to develop and commercialize Remoxy ...
Pain Therapeutics and Durect Stung by Pfizer Move - 24/7 Wall St.
Pfizer Ends Agreement to Develop Remoxy - Wall Street Journal
UPDATE 2-Pfizer meningitis vaccine wins US approval
Reuters - Oct 29, 2014
Oct 29 (Reuters) - Pfizer Inc has won U.S. approval for its Trumenba vaccine against meningitis B, a potentially deadly bacterial disease that has recently caused outbreaks on college campuses, the U.S.
Pfizers Trumenba Gains Accelerated Approval in the U.S. -
Can This 1 Breast Cancer Drug Turn Pfizer Inc. Into a Growth Stock?
Motley Fool - Oct 20, 2014
Big Pharma is undergoing a radical face-lift due to the avalanche of top-selling drugs losing patent protection. The consequences of the aptly named "patent cliff" have been widespread and immense in scope.
Stocks to Watch: Pfizer, DuPont, Whirlpool
Wall Street Journal (blog) - Oct 28, 2014
Among the companies with shares expected to actively trade in Tuesday's session are Pfizer Inc., DuPont Co. and Whirlpool Corp.
Should Pfizer Inc. Buy This Surprisingly Competitive Biotech Stock?
Motley Fool - Oct 7, 2014
PCSK9 inhibitors, and their potential sales, have garnered a lot of interest from investors Pfizer's (NYSE: PFE ) Lipitor peaked at well over $10 billion in annual sales.
Pfizer Approves $11B Stock Repurchase Plan
ABC News - Oct 23, 2014
Pfizer Inc. is the world's second-largest drugmaker, and its products include the vaccine Prevnar and pain and fibromyalgia treatment Lyrica.
Pfizer Stock Buyback Plan Just Too Large to Ignore — It Is on Viagra - 24/7 Wall St.
Pfizer Announces It Will Buy Back $11 Billion in Shares - Bloomberg
Pfizer To Report Lower Earnings and Revenue For Q3FY14
Bidness ETC - Oct 27, 2014
Pfizer Inc. (PFE) is due to announce financial and operational results for the third quarter of its 2014 fiscal year (3QFY14) before the US markets open for trading on Tuesday.